Treatment of hereditary autoinflammatory diseases

Current Opinion in Rheumatology

Volumn 26, Issue 3, 2014, Pages 252-258

  Ter Haar, Nienke M ^a   Frenkel, Joost ^b  

^a Department of Pediatric Rheumatology ^*  (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

autoinflammatory disease; familial mediterranean fever; interleukin 1; periodic fever

Indexed keywords

CANAKINUMAB; COLCHICINE; CORTICOSTEROID; ETANERCEPT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; BIOLOGICAL PRODUCT; INTERLEUKIN 1;

AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; BODY WEIGHT; CINCA SYNDROME; CLINICAL RESEARCH; DISEASE ACTIVITY SCORE; DRUG EFFICACY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; INTERLEUKIN 36 RECEPTOR ANTAGONIST DEFICIENCY; MEVALONATE KINASE DEFICIENCY; NLRP 12 RELATED PERIODIC FEVER; PATIENT CARE; PRIORITY JOURNAL; PYOGENIC ARTHRITIS PUSTULOSIS ACNE SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HEREDITARY AUTOINFLAMMATORY DISEASES; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL PRODUCTS; COLCHICINE; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FAMILIAL MEDITERRANEAN FEVER; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INTERLEUKIN-1; MEVALONATE KINASE DEFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84897550349     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000059     Document Type: Review

References (22)

1. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65:2499-2512.
2. Pouchot J, Arlet JB. Biological treatment in adult-onset Still's disease. Best Pract Res Clin Rheumatol 2012; 26:477-487.
3. Almeida de Jesus A, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 2013; 147:155-174.
4. TerHaar N, Lachmann H, Ozen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72:678-685.
5. Berkun Y, Wason S, Brik R, et al. Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. Int J Immunopathol Pharmacol 2012; 25:1121-1130.
6. Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 2012; 161:1142-1146.
7. Lidar M, Yonath H, Shechter N, et al. Incomplete response to colchicine in M694 V homozygote FMF patients. Autoimmun Rev 2012; 12:72-76.
8. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum 2013; 43:387-391.
9. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicineresistant or-intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157:533-541.
10. Hoffman HM, Throne ML, Amar NJ, et al. Long-termefficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 2012; 34:2091-2103.
11. Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three-and five-year outcomes. Arthritis Rheum 2012; 64:2375-2386.
12. Patients with NOMID, the most severe CAPS phenotype, were followed for at least 3 year to determine long-term anakinra efficacy. Anakinra could prevent damage progression and improved hearing and vision in some patients too.
13. Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther 2013; 15:R64.
14. Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 2012; 51: 1855-1859.
15. van der Burgh R, Ter Haar NM, Boes ML, et al. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol 2013; 147:197-206.
16. Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol 2013; 149:209-215.
17. Simonini G, Xu Z, Caputo R, et al. Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 2013; 65:513-518.
18. Piram M, Kone-Paut I, Lachmann HJ, et al. Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 2013.
19. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med 2014; 65:223-244.
20. Urien S, Bardin C, Bader-Meunier B, et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol 2013; 14:40.
21. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119:e474-e483.
22. Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011; 29 (4 Suppl 67):S77-S86.